Related by context. All words. (Click for frequent words.) 75 ipsilateral stroke 75 binary restenosis 74 recurrent VTE 74 XIENCE V PROMUS Stent 72 MACCE 72 Stent thrombosis 72 TEAEs 72 virologic failure 72 symptomatic VTE 71 pCR 71 periprocedural 71 HbA 1c levels 71 thromboembolic events 71 evaluable subjects 71 perioperative mortality 71 PASI scores 71 CYPHER Stent 70 reinfarction 70 nonfatal MI 70 arterial thromboembolic events 70 postintervention 70 mg BID dose 70 mg kg dose 70 certolizumab 70 advanced adenoma 70 ALT flares 69 carotid stenosis 69 relapsed MM 69 rebleeding 69 repeat revascularization 69 NNRTI resistance 69 hematologic toxicity 69 stent thromboses 69 morphometric vertebral fractures 69 CVD mortality 69 thromboembolic 69 colorectal adenoma 69 CCyR 69 recurrent ischemia 69 SUVmax 69 KRAS mutations occur 69 Kaplan Meier analysis 69 EDSS score 69 mcg albinterferon alfa 2b 69 XIENCE V demonstrated 69 elevated ALT 68 myocardial infarctions 68 advanced adenomas 68 seroprotection 68 postoperative mortality 68 virologic response 68 ARB telmisartan 68 complete cytogenetic response 68 nondiabetic patients 68 systemic embolism 68 composite endpoint 68 placebo dexamethasone 68 severe neutropenia 68 MMSE scores 68 discontinuations due 68 vertebral fracture 68 oral allopurinol 68 biochemical recurrence 68 thromboembolic complications 68 subtrochanteric 68 ARCOXIA 68 Operative mortality 68 CANCIDAS 68 HBeAg seroconversion 68 thromboembolism 68 FluCAM arm 68 biochemical relapse 68 CsA 68 thrombotic events 68 NATRECOR ® 68 PSADT 68 NIHSS score 68 doxorubicin docetaxel 68 timepoints 67 coronary stenosis 67 undetectable HBV DNA 67 CR nPR 67 oxycodone CR 67 tirofiban 67 β blockers 67 transaminase elevations 67 LV dysfunction 67 baseline HbA1c 67 tipranavir r 67 achieved ACR# 67 intravenous bisphosphonates 67 sustained virological response 67 adenoma recurrence 67 EDSS scores 67 angiographic outcomes 67 Subgroup analyzes 67 nonvertebral fractures 67 postoperative complication 67 CIN3 67 dalteparin 67 octreotide LAR 67 revascularizations 67 methotrexate monotherapy 67 DLTs 67 lumbar spine BMD 67 HGPIN 67 virological failure 67 laboratory abnormalities 67 SLNB 67 Taxus Stent 67 PSA nadir 67 myocardial infarction MI 67 rFVIIa 67 probable stent thrombosis 67 glycated hemoglobin levels 67 seropositivity 66 death reinfarction 66 HbA1C levels 66 ertapenem 66 genotypic resistance 66 cardiovascular hospitalizations 66 events MACE 66 cerebrovascular events 66 annualized relapse 66 Doxil ® 66 hematological adverse 66 salmeterol HFA MDI 66 chlorambucil 66 severe exacerbations 66 nonfatal myocardial infarction 66 REYATAZ r arm 66 CYPHER ® Stent 66 lymphocytosis 66 nonresponders 66 atheroma volume 66 nonsignificant 66 sirolimus stent 66 hip BMD 66 myocardial infarctions MIs 66 TAXUS Express Stent 66 univariate analysis 66 sirolimus eluting stent 66 perioperative complications 66 recurrent UTI 66 angiographic restenosis 66 postoperative chemotherapy 66 locoregional recurrence 66 serum creatinine levels 66 LVEF 66 MADRS score 66 paclitaxel eluting stents 66 CHD mortality 66 % CI #.#-#.# [007] 66 neurodevelopmental impairment 66 eplerenone 66 STRIDE PD 66 postprocedure 66 QTc prolongation 66 ximelagatran 66 URTI 66 Serious adverse reactions 66 sirolimus eluting stents 66 hemorrhagic complications 66 advanced neoplasia 66 recurrent venous thromboembolism 66 serum estradiol 66 cytogenetic response 66 TAVR 66 lopinavir r arm 66 multivariable analysis 66 preintervention 66 everolimus eluting stents 66 prospectively defined 66 atherothrombotic disease 66 intracranial hemorrhage ICH 66 dose cohort 66 upper gastrointestinal bleeding 66 hsCRP levels 66 neurologic complications 66 serum urate 66 inhospital 66 primary patency 66 carotid IMT 65 ACR# response 65 sUA 65 ARCALYST ® 65 colorectal neoplasia 65 recurrent DVT 65 lipid lowering drugs 65 Postoperative complications 65 coronary revascularization 65 underwent CABG 65 histologic subtype 65 clinico pathological 65 HSCT 65 COPD exacerbation 65 ACR# responses 65 oncologic outcomes 65 virologic breakthrough 65 endometrial thickness 65 events SAEs 65 R# #mg BID 65 intima media thickness 65 unstable angina pectoris 65 hemodynamically significant 65 diameter stenosis 65 VT VF 65 endometrial carcinoma 65 cardiovascular hospitalization 65 macroalbuminuria 65 Complication rates 65 tumor recurrence 65 Index CDAI 65 Events MACE 65 platelet reactivity 65 imipenem 65 receiving VICTRELIS 65 NEVO ™ 65 P = .# 65 PREZISTA r arm 65 prostate cancer CaP 65 thromboses 65 p = NS 65 desvenlafaxine succinate 65 alemtuzumab treated 65 parous women 65 extrapyramidal symptoms 65 neutrophil counts 65 tolvaptan 65 patients undergoing CABG 65 Baseline characteristics 65 multivariate Cox 65 amoxicillin clavulanate 65 FOLPI 65 leucopenia 65 CIMZIA ™ 65 MMSE score 65 Kaplan Meier estimates 65 corticosteroid dose 65 APTIVUS r 65 EXJADE 65 myocardial infarction stroke 65 #mg BID [001] 65 DAS# remission 65 concomitant antibiotics 65 NSTE ACS 65 Hb A1C 65 mcg BID 65 alanine aminotransferase 65 recurrent myocardial infarction 65 invasive aspergillosis 65 antibody titers 64 virological response 64 bronchopulmonary dysplasia 64 prospectively stratified 64 idraparinux 64 subclinical hypothyroidism 64 events AEs 64 T2 lesions 64 seroconversion 64 statistical significance p 64 retrospective cohort 64 confidence interval #.#-#.# 64 A1c levels 64 sustained virologic response 64 endophthalmitis 64 flutamide 64 serum aminotransferase levels 64 thrombotic complications 64 comparator arm 64 spontaneous preterm delivery 64 lymphadenectomy 64 NIHSS 64 ATACAND 64 HbA 1c 64 MCyR 64 posttreatment 64 timepoint 64 nonvertebral fracture 64 HER2 expression 64 FOLFOX4 64 HBeAg positive patients 64 univariate 64 NATRECOR R 64 elotuzumab 64 generalized edema 64 unfractionated heparin 64 secondary efficacy endpoint 64 docetaxel chemotherapy 64 androgen deprivation 64 mm Stent 64 femoral neck BMD 64 endoscopic remission 64 % CI #.#-#.# [003] 64 revascularization procedures 64 dose Iluvien 64 intravitreal injections 64 Pharmacokinetic parameters 64 aldosterone antagonist 64 periprocedural MI 64 pT3 64 colorectal liver metastases 64 oral diclofenac 64 liver histology 64 non valvular atrial 64 splenectomized patients 64 ICD implantation 64 concomitant medications 64 median survivals 64 nadolol 64 ECG abnormalities 64 -#.# log# 64 lipid lowering agents 64 insulin detemir 64 mg/m2 dose 64 Elitek 64 poor metabolizers 64 virologic failures 64 DAS# CRP 64 mcg QD 64 serum clusterin levels 64 dosing cohort 64 invasive carcinomas 64 nonpregnant women 64 paroxysmal AF 64 fragility fracture 64 colorectal polyp 64 serum phosphate 64 hepatorenal syndrome 64 target lesion revascularization 64 mg BID 64 elevated LDH 64 radical nephrectomy 64 nadroparin 64 severe hypoglycemic 64 neurologic outcomes 64 NSTEMI 64 dapagliflozin plus 64 radial artery grafts 64 hypoglycemic events 64 DES implantation 64 fosamprenavir 64 HBeAg negative patients 64 carotid endarterectomy CEA 64 endometrial hyperplasia 64 noncardiac 64 fondaparinux 64 HOMA IR 64 ALT elevation 64 HbA1c levels 64 chorioamnionitis 64 p = #.# [003] 64 complete cytogenetic 64 ACUITY trial 64 preterm deliveries 64 graft occlusion 64 troponin T 64 QTc 64 lipid lowering therapy 64 radical prostatectomy RP 64 mL/min/#.# m 2 64 plus dexamethasone 64 abnormal p# biomarker 64 adjunctive placebo 64 tapentadol ER 64 CIN2 + 63 micafungin 63 postoperative morbidity 63 adalimumab 63 serum PSA 63 T2DM 63 intracerebral hemorrhages 63 Hazard Ratio 63 Erythropoietic therapies may 63 solifenacin 63 confidence intervals CIs 63 squamous histology 63 vaccinees 63 stent thrombosis 63 EBRT 63 albumin excretion 63 daunorubicin 63 Ishak fibrosis score 63 neoadjuvant 63 thromboprophylaxis 63 receiving INTRON 63 PRADAXA #mg 63 intraobserver 63 glomerular filtration 63 zotarolimus 63 hematologic adverse 63 Crohn Disease Activity 63 TAXUS p value 63 HbA 1C 63 NPH insulin 63 incidence ≥ 63 microalbuminuria 63 antibody titer 63 RSV hospitalizations 63 atherogenic dyslipidemia 63 alteplase 63 NNT = 63 TAXUS Stent 63 biologic DMARD 63 serologically active patients 63 QTcF 63 #.#/#.# mmHg [001] 63 ribavirin therapy 63 statistically nonsignificant 63 subgroup analyzes 63 serum calcium levels 63 pT2 63 DAS# [002] 63 renal cell carcinomas 63 mcg dose 63 contralateral breast cancer 63 multivariable analyzes 63 BRCA2 mutation carriers 63 colorectal adenomas 63 visceral metastases 63 febrile neutropenia 63 nonobstructive CAD 63 graft dysfunction 63 IIIa inhibitor 63 serum IGF 63 ALT elevations 63 elevated bilirubin 63 stenoses 63 colorectal cancer incidence 63 atypical ductal hyperplasia 63 tacrolimus ointment 63 CR CRu 63 CYPHER R Sirolimus eluting 63 serum concentrations 63 COPD exacerbations 63 % Confidence Interval 63 EURIDIS 63 peginterferon alfa 2a 63 salmeterol fluticasone propionate 63 curative resection 63 intracerebral hemorrhage 63 PAOD 63 mg QD 63 intraventricular hemorrhage 63 histologically confirmed 63 R0 resection 63 mCi kg 63 leukopenia 63 urinary N telopeptide 63 Non inferiority 63 TNF antagonist 63 mg TID 63 achieved statistical significance 63 coronary calcification 63 postoperative infection 63 GLIADEL R Wafer 63 external genital lesions 63 HDRS 63 secondary efficacy endpoints 63 reintervention 63 ABC/3TC 63 systolic dysfunction 63 renal dysfunction 63 elevated troponin 63 aspartate aminotransferase AST 63 baseline A1C 63 venous thrombosis 63 liver transplant recipients 63 posaconazole 63 prolonged QT interval 63 mycophenolate mofetil 63 nodal metastases 63 autonomic dysfunction 63 IOP lowering 63 symptomatic intracerebral hemorrhage 63 mcg doses 63 SVR# 63 metastatic RCC 63 PREZISTA r 63 seroconverted 63 serum testosterone 63 symptomatic intracranial 63 steroid dexamethasone 63 statistically significant p = 63 aged ≥ 63 conditional logistic regression 63 postoperative complications 63 mg ustekinumab 63 CC genotype 63 venous thromboembolism 63 evaluable 63 mcg kg REBETOL 63 ug dose 63 intravesical therapy 63 urolithiasis 63 cerebral microbleeds 63 non squamous NSCLC 63 onset atrial fibrillation 63 Primary endpoints 63 SYNTAX trial 63 iodixanol 63 lamivudine monotherapy 63 aminotransferase elevations greater 63 venous thromboembolic events 63 dosage regimens 63 carotid intima media 63 somatostatin analog 63 prespecified 63 underwent resection 63 confidence interval CI 63 recurrent ischemic stroke 63 ICD implants 63 TT genotype 63 anemia hemoglobin 63 Scale EDSS score 63 microbiological eradication 63 carboplatin paclitaxel 63 cobiprostone 63 NHANES III 63 alanine aminotransferase ALT 63 Lucentis monotherapy 63 peripheral sensory neuropathy 63 clinicopathological features 63 postdischarge 63 acromegalic patients 63 AST ALT 63 target vessel revascularization 63 paclitaxel eluting stent 63 femoral shaft fracture 63 CLL SLL 63 Subgroup analysis 63 clinically meaningful improvement 63 Infusion Reactions Severe 63 distant metastasis 63 vertebral fractures 63 cilostazol 63 locoregional 62 radiochemotherapy 62 neoadjuvant therapy 62 EpCAM expression 62 hypercalcemia 62 fluvastatin 62 mCRC patients 62 highest tertile 62 IIIa inhibitors 62 leukocyte count 62 nonfatal stroke 62 MetS 62 CHD CVD 62 5-FU/LV 62 locoregional disease 62 remission CR 62 pericardial effusion 62 ADHF 62 CDAI score 62 atypical hyperplasia 62 beta blocker therapy 62 Thrombolysis 62 logistic regression models 62 rFSH 62 perioperative morbidity 62 ischemic cardiomyopathy 62 macrovascular events 62 Serious AEs 62 mcg Albuferon 62 mITT population 62 atherothrombotic events 62 candidemia 62 Median survival 62 inhospital mortality 62 median PFS 62 hepatocellular carcinomas 62 neonatal morbidity 62 TMC# r 62 chronic periodontitis 62 SAEs 62 serum phosphate levels 62 Folfox 62 proximal DVT 62 μmol L 62 VELCADE melphalan 62 TORISEL 62 BRCA1 mutation carriers 62 efficacy endpoint 62 hepatic resection 62 carotid artery stenting CAS 62 thrombocytopenic 62 psychiatric comorbidities 62 glycated hemoglobin HbA1c 62 familial aggregation 62 VcMP 62 asthma exacerbation 62 IFN alfa 62 CTEPH 62 #mg/day [001] 62 GnRH agonists 62 noninferiority 62 FDA defined valvulopathy 62 dose statin therapy 62 mean baseline A1C 62 LV ejection fraction 62 hepatectomy 62 ELBW infants 62 HBV infections 62 INCB# [003] 62 severe rotavirus gastroenteritis 62 gout flares 62 metastatic CRC 62 logistic regression analysis 62 histological subtype 62 interferon beta therapy 62 nonfasting triglyceride levels 62 lispro 62 preoperative chemotherapy 62 recurrent glioblastoma multiforme 62 asymptomatic PAD 62 postoperative AF 62 intraoperative complications 62 nonrandomized 62 microbiologically evaluable 62 Free Survival PFS 62 postmenopausal osteoporotic women 62 melphalan prednisone 62 cerebral vasospasm 62 ALND 62 bendamustine 62 heavily pretreated 62 LEXIVA r 62 detectable HCV RNA 62 preoperative PSA 62 onset diabetes mellitus 62 cryptogenic stroke 62 virologic responses 62 HF hospitalization 62 hemagglutination inhibition 62 multivariate analyzes 62 deep venous thromboses 62 CYPHER ® 62 colorectal neoplasms 62 underwent surgical resection 62 â ‰ ¥ 62 plus MTX 62 NYHA functional class 62 sternal wound infections 62 attain statistical significance 62 androgen suppression 62 Adverse events 62 cisplatin vinorelbine 62 logistic regression model 62 symptomatic aortic stenosis 62 neutropenia dehydration dyspnea 62 grade cervical intraepithelial 62 segment binary restenosis 62 RRMS patients 62 intact parathyroid hormone 62 ULORIC 62 NIH CPSI 62 invasive ductal 62 ACR# ACR# 62 distant metastases 62 rimonabant #mg 62 unfractionated heparin UFH 62 Febrile neutropenia 62 progression TTP 62 salmeterol fluticasone 62 DAPT 62 #mg/m# [001] 62 HER2 overexpression 62 RE LY ® 62 follicular lymphomas 62 CMV disease 62 Hazard Ratio HR 62 carotid artery narrowing 62 interquartile range 62 echocardiographic parameters 62 tenecteplase 62 hemoglobin A1c levels 62 serum urate levels 62 severe asthma exacerbations 62 TMP SMX 62 multivariable adjusted 62 serum HCV RNA 62 mcg linaclotide 62 acute cholecystitis 62 transaminases 62 VaD 62 pyelonephritis 62 contrast induced nephropathy 62 interobserver reliability 62 adnexal mass 62 Response Evaluation Criteria 62 abciximab 62 TKAs 62 HBeAg 62 Multivariate analysis 62 rizatriptan 62 adjuvant radiation 62 enoxaparin 62 hyperbilirubinemia 62 hypomagnesemia 62 SORT OUT III 62 endarterectomy 62 NovoTTF 62 receiving Vectibix monotherapy 62 FOLFIRI 62 caspofungin 62 incontinence episodes 62 seropositive patients 62 confirmed thrombotic cardiovascular 62 telaprevir dosing 62 hip resurfacing arthroplasty 62 gastric pH 62 antithrombotic therapy 62 PRADAXA 62 epoetin alpha 62 NP CRNs 62 FluCAM 62 noninferior 62 antiarrhythmic drug 62 Aspergillus infections 62 HBeAg negative 62 Logistic regression 62 cardioembolic stroke 62 discontinuations 62 invasive candidiasis 62 serum PTH 62 ejection fractions 62 cTnT 62 nucleoside naive patients 62 neutropenic fever 62 #Gy 62 HAM D# scores 62 reoperations 62 OPCAB 62 CIN3 + 62 VTEs 62 serum ALT 62 undergone radical prostatectomy 62 multivariate adjustment 62 irbesartan 62 mg Proellex 62 urate lowering therapy 62 mEq L 61 tigecycline 61 dyslipidaemia 61 fasting glucose levels 61 transaminase levels 61 receiving ISENTRESS 61 cerebral infarction 61 hematologic parameters 61 nonmelanoma skin cancer 61 inhaled budesonide 61 preoperative radiotherapy 61 SCr 61 sham injections 61 stable angina 61 hepatic metastases 61 8mg/kg 61 complete remissions 61 % CI #.#-#.# [006] 61 mRCC 61 dose clopidogrel 61 argatroban 61 infarct size 61 renal tumors 61 mediastinitis 61 Cypher Stent 61 partial remissions 61 Pegasys plus Copegus 61 prospectively enrolled 61 pegylated interferon alfa 2b 61 Renal Cell Carcinoma RCC 61 microbleeds 61 extracapsular extension 61 FROVA 61 Platelet counts 61 tapentadol IR 61 receiving golimumab 61 % CI #.#-#.# [008] 61 nonoperative treatment 61 debulking surgery 61 low dose Iluvien 61 BENICAR HCT 61 plasma cortisol 61 lymph node involvement 61 aspirin clopidogrel 61 UGT#A# * 61 XIENCE V vs. 61 aspartate aminotransferase 61 oral Hycamtin 61 CrCl 61 serum bilirubin 61 OGTT 61 dysglycemia 61 intraocular inflammation 61 dose dabigatran 61 noncarriers 61 polyp recurrence 61 Angiographic 61 pulmonary exacerbations 61 clodronate 61 Solid Tumors criteria 61 antiretroviral naïve 61 Target Lesion Revascularization TLR 61 doxorubicin cyclophosphamide 61 pyrexia mucositis sepsis febrile 61 rosuvastatin #mg 61 post thrombotic syndrome 61 randomized controlled trials RCTs 61 eptifibatide 61 postoperative infections 61 bacteriuria 61 chemoradiation therapy 61 nab paclitaxel 61 HORIZONS AMI trial 61 spontaneous preterm birth 61 ischemia driven 61 axillary node 61 hepatitis C genotype 61 #mmHg [001] 61 CRESTOR #mg 61 carotid plaque 61 unfavorable prognostic 61 sleeve lobectomy 61 X ULN 61 gastrointestinal toxicities 61 glargine 61 refractory ischemia 61 tolterodine ER 61 treatment emergent adverse 61 GAMMAGARD 61 KIF6 carriers 61 empyema 61 nonoperative 61 syncopal 61 Flu Cy 61 PCa 61 bolus dose 61 MGUS 61 cerebrovascular accidents 61 extracolonic findings 61 nonobese 61 atorvastatin #mg 61 cervical intraepithelial neoplasia 61 femoral neck fracture 61 odds ratios ORs 61 Hycamtin ® 61 coinfected patients 61 treatment emergent AEs 61 acute aortic dissection 61 hyperintense lesions 61 dual antiplatelet therapy 61 DAS# scores 61 TAXUS stent 61 CI #.#-#.# [001] 61 specific antigen PSA 61 infarcts 61 valvular disease 61 prednisone prednisolone 61 nonfasting triglycerides 61 basal cell carcinoma BCC 61 placebo fluoxetine 61 serum lipid levels 61 stent binary restenosis 61 myocardial ischemia 61 gadobutrol 61 aldosterone antagonists 61 STEMI patients 61 Tumor shrinkage 61 intestinal metaplasia 61 aminotransferase levels 61 RSD# oral 61 UPDRS scores 61 mg kg cohorts 61 perinatal mortality 61 decitabine 61 ischemic lesions 61 neutropaenia 61 TAXUS Liberte Stent 61 receiving prophylactic anticoagulation 61 mammographic density 61 symptomatic carotid stenosis 61 pravastatin therapy 61 intravenous diuretics 61 plain radiographs 61 chemoradiotherapy 61 foveal thickness 61 log# copies mL 61 hydroxyvitamin D levels 61 lanthanum carbonate 61 serum cortisol 61 salpingo oophorectomy 61 IELT 61 Kaplan Meier curves 61 TURBT 61 cytogenic 61 DVT PE 61 ExTRACT TIMI 61 levosimendan 61 CIMZIA TM certolizumab pegol 61 CK MB 61 atrioventricular block 61 ACEI ARB 61 #mg QD [002] 61 venlafaxine XR 61 thyrotropin levels 61 infusional 5-FU/LV 61 #mg BID [003] 61 adenotonsillectomy 61 EBUS FNA 61 stent implantation 61 recurrent wheezing 61 cardiogenic shock 61 recanalization 61 severe hypersensitivity reactions 61 dose dexamethasone 61 nondepressed 61 ABCB1 61 CMV infection 61 overt nephropathy 61 cinacalcet 61 tHcy 61 prior chemotherapy regimens 61 conjunctival hyperemia 61 Engerix B 61 thrombolytic agents 61 saline placebo 61 antithrombotic therapies 61 fibrinolysis 61 node metastases 61 abacavir lamivudine 61 placebo p = 61 p# biomarker 61 serous ovarian cancer 61 posttransplant 61 NMIBC 61 VTE prophylaxis 61 metastatic lung cancer 61 estimated GFR 61 histologies 61 COPERNICUS 61 dose cytarabine 61 nonmelanoma skin cancers 61 microg 61 fasting insulin 61 plus medroxyprogesterone acetate 61 hypoperfusion 61 euthyroid 61 ASCUS 61 NYHA Class II 61 coronary revascularization procedures 61 hematopoietic cancers 61 baseline LDH 61 creatinine ratio 61 resected pancreatic cancer 61 follicular lymphoma FL 61 Ceplene/IL-2 61 concomitant AEDs 61 patients evaluable 61 N telopeptide 61 teriflunomide 61 CLA supplementation 61 mmHg diastolic 61 ARIXTRA 61 Univariate analysis 61 Resolute DES 61 hyperphenylalaninemia HPA due 61 AGILECT ® 61 tumor lysis syndrome 61 4mg/kg 61 p = .# [002] 61 Bonferroni correction 61 pimecrolimus cream 61 total thyroidectomy 61 acute myocardial infarctions 61 ACTEMRA TM 61 clinically meaningful improvements 61 GPIIb IIIa inhibitors 61 plus methotrexate 61 VTE 61 epithelial ovarian cancer 61 PRECiSE 61 de ath 61 pegylated liposomal doxorubicin 61 nephrotoxicity 61 systolic BP 61 #mg doses [002] 61 biopsy Gleason 61 comorbid conditions 61 metastatic GIST 61 lenalidomide dexamethasone 61 moderately emetogenic 61 Renal impairment 61 eGFR 61 plus gemcitabine 61 thrombus aspiration 61 apnea hypopnea index 60 unstable angina UA 60 Carotid Revascularization Endarterectomy vs.